NEWS
New integrated analyser for satellite labs
Beckman Coulter Diagnostics has launched its new DxC 500i integrated clinical chemistry and immunoassay analyser. Ideally suited for satellite and independent laboratories, the DxC 500i offers flexibility, scalability and data commutability with an extensive assay menu.
Utilising Beckman Coulter’s common
reagents and consumables across its scalable clinical chemistry and immunoassay portfolio, the DxC 500i analyser enables commutable patient results, offering hospitals and healthcare networks strategic benefits in patient care and inventory management. “The development of the DxC 500i analyser is yet another example of how Beckman Coulter is investing in the needs of a broad range of laboratories across healthcare systems,” said Kathleen Orland, Senior Vice President, Business Unit, General Manager, Chemistry and Immunoassay for Beckman Coulter Diagnostics. “The DxC 500i powers both clinical chemistry and immunoassay testing in one space-saving package. With steadfast performance, practical simplicity, and trusted clinical quality, this analyser meets the specific demands of the low- volume laboratory customer, standalone laboratories and community hospitals.” The DxC 500i features FlexMode operations, prioritising immunoassay and chemistry testing according to each sample’s urgency. The new dynamic sample handler manages repeats and re- runs without operator intervention and pulls in a new sample rack as soon as the previous rack is offloaded, optimising rapid throughput in a compact footprint. Of equal importance, the DxC 500i’s intuitive interface supports even the newest users through proactive task indicators, step-by-step instructions and simplified staff onboarding and training. The DxC 500i is currently available in countries accepting the CE mark.
US funding for Moderna to develop influenza vaccines
Moderna has announced a project award of $176 million through the Rapid Response Partnership Vehicle (RRPV) to accelerate the development of mRNA- based pandemic influenza vaccines. The RRPV is a Consortium funded by the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). The project award will support late-stage development for an mRNA- based vaccine to enable the licensure of a pre-pandemic vaccine against H5 influenza virus. This subtype of influenza virus causes a highly infectious, severe disease in birds called avian influenza and poses a risk for spillover into the human population. The agreement also includes additional options to prepare and accelerate a response to future public health threats.
“mRNA vaccine technology offers advantages in efficacy, speed of development, and production scalability and reliability in addressing infectious disease outbreaks, as demonstrated during the COVID-19 pandemic,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We are pleased to continue our collaboration with BARDA to expedite our development efforts for mRNA-based pandemic influenza vaccines and support the global public health community in preparedness against potential outbreaks.”
In 2023, Moderna initiated a Phase 1/2 study to generate safety and immunogenicity data of investigational pandemic influenza vaccine (mRNA- 1018) in healthy adults 18 years of age and older. The study includes vaccine candidates against H5 and H7 avian influenza viruses. Results from the study are expected in 2024 and will inform Phase 3 development plans.
Professor Sarah Coupland elected PathSoc President
Professor Sarah Coupland has been elected President of the Pathological Society of Great Britain and Ireland (PathSoc) following the Society’s recent Annual General Meeting in Sheffield. Professor Coupland is
the current ‘George Holt Chair of Pathology’ at the University of Liverpool, and leads the world- renowned Liverpool Ocular Oncology Research Group, comprising 30 clinicians, scientists and students. LOORG’s research focuses on ocular melanomas, lymphomas and other eye cancers, and employs high-resolution techniques to better understand the development/ progression of these tumours, to improve patient outcome.
A senior Consultant Histopathologist at the Liverpool University Foundation Hospital Trusts with expertise in Ophthalmic Pathology,
12
Haematopathology, Molecular Pathology, and Biobanking, Professor Coupland also leads one of the four superregional NHSE eye pathology services, receiving ophthalmic samples from a broad geographical area, and enabling trainees from the UK and overseas to experience ocular and molecular pathology. Professor Coupland said: “It is a great honour
and privilege for me to take on this role. PathSoc is the oldest organisation promoting academic pathology – it was established in 1906 and has been instrumental in maintaining advances in medicine and pathological sciences over the last 118 years. Its journals, which include The Journal of Pathology and The Journal of Pathology: Clinical Research are high impact and full of cutting-edge research.”
AUGUST 2024
WWW.PATHOLOGYINPRACTICE.COM
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52
